| Similar Articles |
|---|
 |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.   |
Bio-IT World
November 2006
Kevin Davies |
Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
Chemistry World
June 12, 2014
Philli Broadwith |
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
March 9, 2009
Brian Orelli |
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
December 12, 2007
Brian Orelli |
What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
December 10, 2008
Brian Orelli |
Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline. |
Bio-IT World
March 2006 |
News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration... |
The Motley Fool
September 21, 2006
Brian Lawler |
Sayonara, Serono The tiny, struggling drugmaker succumbs to a surprise buyout by German pharmaceutical company Merck KGaA. Investors, take note. |
The Motley Fool
November 30, 2004
Rich Smith |
Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves. |
The Motley Fool
October 16, 2007
Brian Orelli |
Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
The Motley Fool
June 30, 2008
Brian Orelli |
A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug. |
The Motley Fool
April 3, 2007
Brian Lawler |
Merck Gets the Combo Merck gets marketing approval for a diabetes combination drug. Investors, take note. |
The Motley Fool
September 7, 2007
Brian Orelli |
Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells. |
The Motley Fool
February 25, 2004
Brian Gorman |
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
May 12, 2010
Brian Orelli |
Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
September 11, 2008
Brian Orelli |
Vive le Vioxx Lawsuit Just when Merck thought it was finally done with lawsuits pertaining to Vioxx, it's gotten pulled back in. |
The Motley Fool
October 5, 2011
Arlene Weintraub |
Merck Fine-Tunes Biosimilars Strategy as FDA Guidelines Loom Merck readies itself to enter this potential new market. |
The Motley Fool
June 22, 2004
Charly Travers |
Merck Pays Up for a Cancer Drug As demonstrated this morning with the announcement of a major deal with Vertex Pharmaceuticals, Merck is now in the midst of a strategic push to build out its oncology pipeline. |
The Motley Fool
September 18, 2007
Brian Orelli |
Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
BusinessWeek
November 24, 2010
Tom Randall |
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. |
The Motley Fool
November 30, 2007
Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way. |
The Motley Fool
February 16, 2010
Brian Orelli |
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
January 25, 2005
Stephen D. Simpson |
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. |
The Motley Fool
October 23, 2007
Brian Orelli |
Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter. |
The Motley Fool
January 31, 2005
Stephen D. Simpson |
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. |
BusinessWeek
September 5, 2005
Gene G. Marcial |
AtheroGenics May Be A Buyout AtheroGenics is one of the more attractive acquisition candidates of Merck or Pfizer. |
The Motley Fool
October 22, 2008
Brian Orelli |
Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013. |
The Motley Fool
September 1, 2009
Brian Orelli |
Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch. |
The Motley Fool
November 29, 2010
Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
